Pazopanib Followed by Nivolumab Shows Real-World Benefit in Metastatic RCC

The study  of sequential treatment of pazopanib followed by nivolumab in advanced or metastatic renal cell carcinoma looked at benefit-risk profile and survival.

Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news